Abstract: . . .  for the for the Reduction of Events During Reduction of Events During Observation (CREDO) Observation (CREDO) Multi Multi - - center, double center, double - - blind, randomized trial blind, randomized trial 2,000 patients undergoing planned or highly 2,000 patients undergoing planned or highly probable coronary intervention with a probable coronary intervention with a stent stent Will evaluate the efficacy and safety of Will evaluate the efficacy and safety of clopidogrel clopidogrel pretreatment versus no pretreatment pretreatment versus no pretreatment prolonged (1 year) versus short prolonged (1 year) versus short - - term (1 month) term (1 month) dual dual antiplatelet antiplatelet therapy therapy Page 33 a Page 34 b Page 35 c Page 36 Stent Stent Coatings Coatings Passive Passive Thromboresistance Thromboresistance Intact Coatings Designed to Reduce Intact Coatings Designed to Reduce Stent Stent Surface Surface Thrombogenicity Thrombogenicity  . . .
. . .  Thrombosis Thrombosis Case report of patient who developed Case report of patient who developed late late stent stent thrombosis 7 months after thrombosis 7 months after paclitaxel paclitaxel - - eluting eluting stent stent implantation implantation Follow up angiography revealed Follow up angiography revealed persistent optimal result persistent optimal result Ticlopidine Ticlopidine was discontinued ( was discontinued ( asa asa continued) continued) Pt developed thrombosis 15 days later Pt developed thrombosis 15 days later Liistro and Colombo. Heart 2001;86:262-264. Page 52  . . .
--3000,2,750,2528,23701